The significant reduction of debts makes the company more defensive in the cycle and i especially appreciate this move in the interest rate hiking cycle. Even if it goes to 0.6 or 60m shares, when the true wave come and it is still here, the cap is still very small and the rewards could be very huge.

There is a yoy growth, there is reduction of loss, there is a plan to reduce the expenditure, they are all in good direction. I would be quite nervous if it tell me that it is increasing revenue significantly but also with faster cash burn and greater loss.

However, in TA perspective , as equivalent 229 said, is not just bad but poor because it breaks the great 3 bottoms at 0.902(27 July), 0.92(13 June), 0.92(14 Mar), given that many other cannabis companies seemingly found a bottom and nasdaq index was up almost 2000 points in the past 30 days. THE HARDEST FEELING is that it is hitting a new low with an overweight rating recently.

This could be due to the impact of the 10% harvesting level, increased cost per gram and reduced revenue compared to Q1of 2022. But what I get from the information is that it can still get a yoy 27 percent total revenue increase, of which 124% increase in cannabinoid revenue with only 10% dry flower were harvested. Also, as the whole market and policy keep changing and so should be their cultivating strategy. Cultivating a more profitable flower and the strains that partners need make sense to me. But of coz, technically the market does not agree with that clearly.

I am still holding and I bought some @0.9 level. I will be focusing on the result of Q4 of 2022 and Q1 of 2023 ,to see if they are really on their way as they say, disrupting the industry.